Loading…
HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer
Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the HLA-G 3′ untranslated region (UTR) regulate HLA-G expression, we investigated HLA-G 3′UTR...
Saved in:
Published in: | Scientific reports 2019-04, Vol.9 (1), p.5407, Article 5407 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3 |
container_end_page | |
container_issue | 1 |
container_start_page | 5407 |
container_title | Scientific reports |
container_volume | 9 |
creator | Schwich, Esther Rebmann, Vera Michita, Rafael Tomoya Rohn, Hana Voncken, Jan Willem Horn, Peter A. Kimmig, Rainer Kasimir-Bauer, Sabine Buderath, Paul |
description | Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the
HLA-G
3′ untranslated region (UTR) regulate HLA-G expression, we investigated
HLA-G
3′UTR haplotypes arranged by SNPs in healthy controls (n = 75) and primary EOC patients (n = 79) and determined soluble HLA-G (sHLA-G) levels. Results were related to the clinical status and outcome. Although haplotype frequencies were similar in patients and controls, (i) sHLA-G levels were increased in EOC independent of the haplotype, (ii) homozygosity for UTR-1 or UTR-2 genotypes were significantly associated with metastases formation and presence of circulating tumor cells before therapy, whereas (iii) the UTR-5 and UTR-7 haplotypes were significantly associated with a beneficial clinical outcome regarding negative nodal status, early FIGO staging, and improved overall survival. Lastly, (iv) the ambivalent impact on clinical EOC aspects could be deduced to specific SNPs in the
HLA-G
3′UTR: +3187G, +3196G and +3035T alleles. Our results give evidence that even if the genetic background of the
HLA-G
3′UTR is identical between patients and controls, certain SNPs have the potential to contribute to diametrical clinical status/outcome in EOC. |
doi_str_mv | 10.1038/s41598-019-41900-z |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6443684</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2201711228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3</originalsourceid><addsrcrecordid>eNp9kc9qFTEUxgdRbKl9ARcScCPYsfk3yWQjlGJvhQtu6jpkMmduU2aSa5Ip2JWv4Wv4SD6JuXdqrS4MgXyH_M45Ofmq6iXB7whm7WnipFFtjYmqOVEY13dPqkOKeVNTRunTR_qgOk7pBpfVUFXY59UBw4rREh9W3y_XZ_UKsZ_ffqDZ52h8Gk2GHkXYuODRrYnO-JzQW0ZauTpdneyUEkUh4_sSYNZcoR4G5wH1zkyQo7NmRHZ0fi9SNnlOe7p3CUwCFOZswwTIeQRbl69hdAUMSzNkjbcQX1TPBjMmOL4_j6rPFx-uzi_r9afVx_OzdW255LnmCrdSdI3hHIau48R0lBMhWiGgb1oJwrRWykGoXg2DbKwUvWJYCMU4xwLYUfV-qbuduwl6C7tfGPU2usnErzoYp_--8e5ab8KtFpwz0fJS4M19gRi-zJCynlyyMI7GQ5iTphQTSQilbUFf_4PehDn6Mt5Cld3IQtGFsjGkFGF4eAzBeme-XszXxXy9N1_flaRXj8d4SPltdQHYAqRy5TcQ__T-T9lfi3y50A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2201701757</pqid></control><display><type>article</type><title>HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Full-Text Journals in Chemistry (Open access)</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Schwich, Esther ; Rebmann, Vera ; Michita, Rafael Tomoya ; Rohn, Hana ; Voncken, Jan Willem ; Horn, Peter A. ; Kimmig, Rainer ; Kasimir-Bauer, Sabine ; Buderath, Paul</creator><creatorcontrib>Schwich, Esther ; Rebmann, Vera ; Michita, Rafael Tomoya ; Rohn, Hana ; Voncken, Jan Willem ; Horn, Peter A. ; Kimmig, Rainer ; Kasimir-Bauer, Sabine ; Buderath, Paul</creatorcontrib><description>Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the
HLA-G
3′ untranslated region (UTR) regulate HLA-G expression, we investigated
HLA-G
3′UTR haplotypes arranged by SNPs in healthy controls (n = 75) and primary EOC patients (n = 79) and determined soluble HLA-G (sHLA-G) levels. Results were related to the clinical status and outcome. Although haplotype frequencies were similar in patients and controls, (i) sHLA-G levels were increased in EOC independent of the haplotype, (ii) homozygosity for UTR-1 or UTR-2 genotypes were significantly associated with metastases formation and presence of circulating tumor cells before therapy, whereas (iii) the UTR-5 and UTR-7 haplotypes were significantly associated with a beneficial clinical outcome regarding negative nodal status, early FIGO staging, and improved overall survival. Lastly, (iv) the ambivalent impact on clinical EOC aspects could be deduced to specific SNPs in the
HLA-G
3′UTR: +3187G, +3196G and +3035T alleles. Our results give evidence that even if the genetic background of the
HLA-G
3′UTR is identical between patients and controls, certain SNPs have the potential to contribute to diametrical clinical status/outcome in EOC.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-019-41900-z</identifier><identifier>PMID: 30932005</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13 ; 13/51 ; 3' Untranslated regions ; 3' Untranslated Regions - genetics ; 38 ; 38/23 ; 38/77 ; 45 ; 631/250/248 ; 631/250/580 ; 692/4028/67/1517/1709 ; Adult ; Aged ; Aged, 80 and over ; Alleles ; Carcinoma, Ovarian Epithelial - genetics ; Carcinoma, Ovarian Epithelial - metabolism ; Carcinoma, Ovarian Epithelial - pathology ; Female ; Gene Frequency ; Genetic Predisposition to Disease - genetics ; Genotype ; Genotypes ; Haplotypes ; Histocompatibility antigen HLA ; HLA-G Antigens - genetics ; HLA-G Antigens - metabolism ; Homozygosity ; Humanities and Social Sciences ; Humans ; Kaplan-Meier Estimate ; Metastases ; Middle Aged ; multidisciplinary ; Neoplasm Staging ; Ovarian cancer ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; Polymorphism, Single Nucleotide ; Science ; Science (multidisciplinary) ; Single-nucleotide polymorphism ; Tumor cells</subject><ispartof>Scientific reports, 2019-04, Vol.9 (1), p.5407, Article 5407</ispartof><rights>The Author(s) 2019</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3</citedby><cites>FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2201701757/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2201701757?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30932005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schwich, Esther</creatorcontrib><creatorcontrib>Rebmann, Vera</creatorcontrib><creatorcontrib>Michita, Rafael Tomoya</creatorcontrib><creatorcontrib>Rohn, Hana</creatorcontrib><creatorcontrib>Voncken, Jan Willem</creatorcontrib><creatorcontrib>Horn, Peter A.</creatorcontrib><creatorcontrib>Kimmig, Rainer</creatorcontrib><creatorcontrib>Kasimir-Bauer, Sabine</creatorcontrib><creatorcontrib>Buderath, Paul</creatorcontrib><title>HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the
HLA-G
3′ untranslated region (UTR) regulate HLA-G expression, we investigated
HLA-G
3′UTR haplotypes arranged by SNPs in healthy controls (n = 75) and primary EOC patients (n = 79) and determined soluble HLA-G (sHLA-G) levels. Results were related to the clinical status and outcome. Although haplotype frequencies were similar in patients and controls, (i) sHLA-G levels were increased in EOC independent of the haplotype, (ii) homozygosity for UTR-1 or UTR-2 genotypes were significantly associated with metastases formation and presence of circulating tumor cells before therapy, whereas (iii) the UTR-5 and UTR-7 haplotypes were significantly associated with a beneficial clinical outcome regarding negative nodal status, early FIGO staging, and improved overall survival. Lastly, (iv) the ambivalent impact on clinical EOC aspects could be deduced to specific SNPs in the
HLA-G
3′UTR: +3187G, +3196G and +3035T alleles. Our results give evidence that even if the genetic background of the
HLA-G
3′UTR is identical between patients and controls, certain SNPs have the potential to contribute to diametrical clinical status/outcome in EOC.</description><subject>13</subject><subject>13/51</subject><subject>3' Untranslated regions</subject><subject>3' Untranslated Regions - genetics</subject><subject>38</subject><subject>38/23</subject><subject>38/77</subject><subject>45</subject><subject>631/250/248</subject><subject>631/250/580</subject><subject>692/4028/67/1517/1709</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alleles</subject><subject>Carcinoma, Ovarian Epithelial - genetics</subject><subject>Carcinoma, Ovarian Epithelial - metabolism</subject><subject>Carcinoma, Ovarian Epithelial - pathology</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>Genetic Predisposition to Disease - genetics</subject><subject>Genotype</subject><subject>Genotypes</subject><subject>Haplotypes</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA-G Antigens - genetics</subject><subject>HLA-G Antigens - metabolism</subject><subject>Homozygosity</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Neoplasm Staging</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Single-nucleotide polymorphism</subject><subject>Tumor cells</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kc9qFTEUxgdRbKl9ARcScCPYsfk3yWQjlGJvhQtu6jpkMmduU2aSa5Ip2JWv4Wv4SD6JuXdqrS4MgXyH_M45Ofmq6iXB7whm7WnipFFtjYmqOVEY13dPqkOKeVNTRunTR_qgOk7pBpfVUFXY59UBw4rREh9W3y_XZ_UKsZ_ffqDZ52h8Gk2GHkXYuODRrYnO-JzQW0ZauTpdneyUEkUh4_sSYNZcoR4G5wH1zkyQo7NmRHZ0fi9SNnlOe7p3CUwCFOZswwTIeQRbl69hdAUMSzNkjbcQX1TPBjMmOL4_j6rPFx-uzi_r9afVx_OzdW255LnmCrdSdI3hHIau48R0lBMhWiGgb1oJwrRWykGoXg2DbKwUvWJYCMU4xwLYUfV-qbuduwl6C7tfGPU2usnErzoYp_--8e5ab8KtFpwz0fJS4M19gRi-zJCynlyyMI7GQ5iTphQTSQilbUFf_4PehDn6Mt5Cld3IQtGFsjGkFGF4eAzBeme-XszXxXy9N1_flaRXj8d4SPltdQHYAqRy5TcQ__T-T9lfi3y50A</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Schwich, Esther</creator><creator>Rebmann, Vera</creator><creator>Michita, Rafael Tomoya</creator><creator>Rohn, Hana</creator><creator>Voncken, Jan Willem</creator><creator>Horn, Peter A.</creator><creator>Kimmig, Rainer</creator><creator>Kasimir-Bauer, Sabine</creator><creator>Buderath, Paul</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190401</creationdate><title>HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer</title><author>Schwich, Esther ; Rebmann, Vera ; Michita, Rafael Tomoya ; Rohn, Hana ; Voncken, Jan Willem ; Horn, Peter A. ; Kimmig, Rainer ; Kasimir-Bauer, Sabine ; Buderath, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>13</topic><topic>13/51</topic><topic>3' Untranslated regions</topic><topic>3' Untranslated Regions - genetics</topic><topic>38</topic><topic>38/23</topic><topic>38/77</topic><topic>45</topic><topic>631/250/248</topic><topic>631/250/580</topic><topic>692/4028/67/1517/1709</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alleles</topic><topic>Carcinoma, Ovarian Epithelial - genetics</topic><topic>Carcinoma, Ovarian Epithelial - metabolism</topic><topic>Carcinoma, Ovarian Epithelial - pathology</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>Genetic Predisposition to Disease - genetics</topic><topic>Genotype</topic><topic>Genotypes</topic><topic>Haplotypes</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA-G Antigens - genetics</topic><topic>HLA-G Antigens - metabolism</topic><topic>Homozygosity</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Neoplasm Staging</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Single-nucleotide polymorphism</topic><topic>Tumor cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwich, Esther</creatorcontrib><creatorcontrib>Rebmann, Vera</creatorcontrib><creatorcontrib>Michita, Rafael Tomoya</creatorcontrib><creatorcontrib>Rohn, Hana</creatorcontrib><creatorcontrib>Voncken, Jan Willem</creatorcontrib><creatorcontrib>Horn, Peter A.</creatorcontrib><creatorcontrib>Kimmig, Rainer</creatorcontrib><creatorcontrib>Kasimir-Bauer, Sabine</creatorcontrib><creatorcontrib>Buderath, Paul</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwich, Esther</au><au>Rebmann, Vera</au><au>Michita, Rafael Tomoya</au><au>Rohn, Hana</au><au>Voncken, Jan Willem</au><au>Horn, Peter A.</au><au>Kimmig, Rainer</au><au>Kasimir-Bauer, Sabine</au><au>Buderath, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>5407</spage><pages>5407-</pages><artnum>5407</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian cancer (EOC). As single nucleotide polymorphisms (SNPs) in the
HLA-G
3′ untranslated region (UTR) regulate HLA-G expression, we investigated
HLA-G
3′UTR haplotypes arranged by SNPs in healthy controls (n = 75) and primary EOC patients (n = 79) and determined soluble HLA-G (sHLA-G) levels. Results were related to the clinical status and outcome. Although haplotype frequencies were similar in patients and controls, (i) sHLA-G levels were increased in EOC independent of the haplotype, (ii) homozygosity for UTR-1 or UTR-2 genotypes were significantly associated with metastases formation and presence of circulating tumor cells before therapy, whereas (iii) the UTR-5 and UTR-7 haplotypes were significantly associated with a beneficial clinical outcome regarding negative nodal status, early FIGO staging, and improved overall survival. Lastly, (iv) the ambivalent impact on clinical EOC aspects could be deduced to specific SNPs in the
HLA-G
3′UTR: +3187G, +3196G and +3035T alleles. Our results give evidence that even if the genetic background of the
HLA-G
3′UTR is identical between patients and controls, certain SNPs have the potential to contribute to diametrical clinical status/outcome in EOC.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30932005</pmid><doi>10.1038/s41598-019-41900-z</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2045-2322 |
ispartof | Scientific reports, 2019-04, Vol.9 (1), p.5407, Article 5407 |
issn | 2045-2322 2045-2322 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6443684 |
source | Publicly Available Content Database (Proquest) (PQ_SDU_P3); Full-Text Journals in Chemistry (Open access); PubMed Central; Springer Nature - nature.com Journals - Fully Open Access |
subjects | 13 13/51 3' Untranslated regions 3' Untranslated Regions - genetics 38 38/23 38/77 45 631/250/248 631/250/580 692/4028/67/1517/1709 Adult Aged Aged, 80 and over Alleles Carcinoma, Ovarian Epithelial - genetics Carcinoma, Ovarian Epithelial - metabolism Carcinoma, Ovarian Epithelial - pathology Female Gene Frequency Genetic Predisposition to Disease - genetics Genotype Genotypes Haplotypes Histocompatibility antigen HLA HLA-G Antigens - genetics HLA-G Antigens - metabolism Homozygosity Humanities and Social Sciences Humans Kaplan-Meier Estimate Metastases Middle Aged multidisciplinary Neoplasm Staging Ovarian cancer Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Polymorphism, Single Nucleotide Science Science (multidisciplinary) Single-nucleotide polymorphism Tumor cells |
title | HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A19%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HLA-G%203%E2%80%B2%20untranslated%20region%20variants%20+3187G/G,%20+3196G/G%20and%20+3035T%20define%20diametrical%20clinical%20status%20and%20disease%20outcome%20in%20epithelial%20ovarian%20cancer&rft.jtitle=Scientific%20reports&rft.au=Schwich,%20Esther&rft.date=2019-04-01&rft.volume=9&rft.issue=1&rft.spage=5407&rft.pages=5407-&rft.artnum=5407&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-019-41900-z&rft_dat=%3Cproquest_pubme%3E2201711228%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-490876b5a44efbb41ab24166866ed587e6a8c77f69d9ff75c76d93066934406e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2201701757&rft_id=info:pmid/30932005&rfr_iscdi=true |